Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1633
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18547840 | Opsins as Chemosensory Receptors and Related Methods | Non-Final OA | The Regents of the University of California |
| 17767822 | STEM CELL-DERIVED MATURE CARDIOMYOCYTES AND CARDIOVASCULAR DISEASE MODEL USING SAME | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18026482 | CELL-SUPPORTING BODY, MANUFACTURING METHOD THEREFOR, CELL CULTURING METHOD, AND CELL STRUCTURE | Final Rejection | Konica Minolta, Inc. |
| 18019931 | PLATFORM VECTOR FOR MODULAR AND SIMPLIFIED INSERTION OF TRANSGENES INTO ALPHAHERPESVIRINAE | Final Rejection | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. |
| 18460022 | METHODS AND COMPOSITIONS FOR GENERATING EMBRYOS IN VITRO FROM PLURIPOTENT STEM CELLS | Non-Final OA | Cambridge Enterprise Limited |
| 18246872 | COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17787161 | 3D TISSUE COMPOSITE AND METHOD OF PRODUCING 3D TISSUE COMPOSITE | Final Rejection | The University Of Tokyo |
| 17779505 | NOVEL AAV3B VARIANTS THAT TARGET HUMAN HEPATOCYTES IN THE LIVER OF HUMANIZED MICE | Non-Final OA | University of Massachusetts |
| 18019421 | METHODS OF TREATING CARDIAC DISORDERS AND CONGESTIVE HEART FAILURE AND ADMINISTERING AAV VECTORS | Non-Final OA | ASKBIO INC. |
| 17863546 | CELL CULTURE MEDIUM COMPOSITION | Non-Final OA | AJINOMOTO CO., INC. |
| 18044047 | MINIATURIZED CYTIDINE DEAMINASE-CONTAINING COMPLEX FOR MODIFYING DOUBLE-STRANDED DNA | Final Rejection | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY |
| 18467089 | Blood Plasma Product | Non-Final OA | Velico Medical, Inc. |
| 17491761 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | Final Rejection | CRISPR Therapeutics AG |
| 18203150 | Methods and Systems for Removing a Histological Stain From a Sample | Non-Final OA | Ultivue, Inc. |
| 18575031 | PHARMACEUTICAL COMPOSITION CONTAINING IRRADIATED HEMATOPOIETIC STEM CELLS | Non-Final OA | JAPANESE RED CROSS SOCIETY |
| 18363663 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA | Non-Final OA | Astellas Institute for Regenerative Medicine |
| 17587973 | ANTITUMOR IMMUNITY ENHANCING COMPOSITION CONTAINING ADENOVIRUS SIMULTANEOUSLY EXPRESSING IL-12 AND SHVEGF | Final Rejection | Genemedicine Co., Ltd. |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | Non-Final OA | WuXi Biologics Ireland Limited |
| 17779458 | METHODS FOR ACTIVATION AND EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES | Non-Final OA | KSQ Therapeutics, Inc. |
| 18366539 | PREVENTION OF SPACE TRAVEL ASSOCIATED BONE DENSITY LOSS BY REGENERATIVE CELL POPULATIONS | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | Final Rejection | National Institute of Biological Sciences, Beijing |
| 18258502 | MODIFIED PARAPOXVIRUS HAVING INCREASED IMMUNOGENICITY | Non-Final OA | PRIME VECTOR TECHNOLOGIES GMBH |
| 18255182 | COMPOSITIONS AND METHODS FOR THE TARGETING OF PTBP1 | Non-Final OA | Scribe Therapeutics Inc. |
| 18039812 | RNA-TARGETING COMPOSITIONS AND METHODS FOR TREATING MYOTONIC DYSTROPHY TYPE 1 | Non-Final OA | Astellas Gene Therapies, Inc. |
| 18251805 | METHOD FOR PRODUCING REVERSIBLY IMMORTALIZED CELL | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY |
| 18025074 | MESENCHYMAL STEM CELLS CO-EXPRESSING CXCR4 AND IL-10 AND USES THEREOF | Non-Final OA | Consorcio Centro de Investigación Biomédica en Red |
| 17617252 | TARGETED GENE EDITING CONSTRUCTS AND METHODS OF USING THE SAME | Non-Final OA | UNIVERSITAT POMPEU FABRA |
| 18157616 | T CELL RECEPTOR (TCR) COMPOSITIONS AND METHODS FOR OPTIMIZING ANTIGEN REACTIVE T-CELLS | Non-Final OA | 3T BIOSCIENCES, INC. |
| 18000718 | METHOD FOR MASS PROLIFERATION OF URINE-DERIVED PLURIPOTENT CELLS | Final Rejection | PURICELLMANIA CO., LTD. |
| 17712864 | NUCLEIC ACID MOLECULES ENCODING AN ENGINEERED ANTIGEN RECEPTOR AND AN INHIBITORY NUCLEIC ACID MOLECULE AND METHODS OF USE THEREOF | Non-Final OA | Precision Biosciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy